| Literature DB >> 35946032 |
Peiman Ghasemi1, Fariba Goodarzian2, Ajith Abraham3, Saeed Khanchehzarrin4.
Abstract
This paper presents a bi-level blood supply chain network under uncertainty during the COVID-19 pandemic outbreak using a Stackelberg game theory technique. A new two-phase bi-level mixed-integer linear programming model is developed in which the total costs are minimized and the utility of donors is maximized. To cope with the uncertain nature of some of the input parameters, a novel mixed possibilistic-robust-fuzzy programming approach is developed. The data from a real case study is utilized to show the applicability and efficiency of the proposed model. Finally, some sensitivity analyses are performed on the important parameters and some managerial insights are suggested.Entities:
Keywords: Bi-level mixed-integer linear programming model; Blood supply chain network; COVID-19 pandemic; Game theory; Mixed possibilistic-robust-fuzzy programming
Year: 2022 PMID: 35946032 PMCID: PMC9352651 DOI: 10.1016/j.apm.2022.08.003
Source DB: PubMed Journal: Appl Math Model ISSN: 0307-904X Impact factor: 5.336
A review of literature on disaster relief.
| Author | Number of objective functions (Single/Multi Objective- (SO)/(MO), Bi-level (Bi)) | Type of objective functions (Cost (C)/ Humanitarian (H)) | Cooperative(C)/Non-cooperative game (N) | Planning horizon (Static-(S), Dynamic (D)) | Data type (Deterministic (D), Uncertain (U)) | Uncertainty sources (Demand (D)/ Production cost(P)/ Transportation cost(T)) | Optimization method (Deterministic (DtO)/ Stochastic (StO)/ Scenario (Sc)/ Robust (Ro), FuzzyOptimization (F)) | COVID-19 condition | Model characteristic | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Donors' utility | Blood Component Extractor | Donor attraction methods | Types of donors | |||||||||
| Zahiri and Pishvaee, | MO | CH | - | D | U | D | F | - | - | - | - | - |
| Ramezanian and Behboodi, | SO | C | - | S | U | D | StO | - | - | - | - | - |
| Heidari-Fathian and Pasandideh, | MO | CH | - | D | U | D | Ro | - | ||||
| Zahiri et al. | MO | CH | - | S | U | DP | StO | - | - | - | - | - |
| Eskandari-Khanghahi et al. | MO | CH | - | D | U | DPT | F | - | ||||
| Habibi-Kouchaksaraei et al. | MO | CH | - | D | U | D | Ro | - | ||||
| Rajendran and Ravindran, | MO | CH | - | D | U | D | F | - | ||||
| Salehi et al. | SO | C | - | D | U | D | Sto | - | ||||
| Rahmani, | SO | C | - | D | D | DT | Ro | - | - | - | - | - |
| Ghorashi et al. | SO | C | - | D | U | D | Ro | - | - | - | - | - |
| Larimi and Yaghoubi | MO | CH | - | D | U | D | Ro | - | ||||
| Hosseini-Motlagh et al. | SO | C | - | D | U | DT | Ro | - | * | |||
| Wang and Chen, | Bi | CH | - | S | U | D | Ro | - | - | - | - | - |
| Haghjoo et al. | SO | C | - | D | U | D | Sc | - | ||||
| Khalilpourazari et al. | MO | CH | - | D | D | - | DtO | - | - | - | - | - |
| Moslemi et al. | MO | CH | - | D | U | D | F | - | ||||
| Our paper | Bi | CH | N | D | U | DPT | F,Ro | * | * | * | * | * |
Fig. 1. The framework of the blood supply chain network.
Fig. 2The structure of the competition mechanism.
Different costs and demand in manufacturing centers and hospitals.
| No. | Hospitals | Manufacturers Transportation cost per 1000 units ($) | Inventory holding cost ($) | Cost of shortage | Cost of BCE allocation ($) | |||
|---|---|---|---|---|---|---|---|---|
| Babolsar | Babol | Sari | Behshahr | |||||
| 1 | Mehr Behshahr | 1700 | 1200 | 1000 | 600 | 8 | 15 | 30,000 |
| 2 | Amiri Behshahr | 2200 | 1700 | 1400 | 700 | 6 | 20 | 25,000 |
| 3 | Bo Ali Neka | 1400 | 1100 | 700 | 400 | 7 | 18 | 40,000 |
| 4 | Bo Ali Sari | 800 | 400 | 300 | 500 | 8 | 15 | 25,000 |
| 5 | Zare Sari | 1000 | 800 | 400 | 500 | 9 | 16 | 30,000 |
| 6 | Shafa Sari | 800 | 450 | 250 | 350 | 6 | 20 | 40,000 |
| 7 | Nime Shaban Sari | 1000 | 800 | 500 | 800 | 7 | 17 | 20,000 |
| 8 | Amir Mzandarani Sari | 650 | 550 | 450 | 600 | 9 | 20 | 30,000 |
| 9 | Velayat Sari | 600 | 400 | 300 | 500 | 9 | 15 | 40,000 |
| 10 | Haj Azizi Juybar | 1200 | 700 | 500 | 700 | 11 | 14 | 50,000 |
| 11 | Kudakan Babol | 700 | 500 | 1200 | 1700 | 7 | 20 | 25,000 |
| 12 | 17 Sahrivar Babol | 900 | 500 | 1700 | 2200 | 7 | 14 | 25,000 |
| 13 | Mehregan Babol | 450 | 300 | 550 | 700 | 7 | 12 | 30,000 |
| 14 | Hazrat Zeinab Babolsar | 400 | 600 | 1200 | 2200 | 10 | 15 | 25,000 |
| 15 | Shafa Babolsar | 400 | 800 | 1700 | 2200 | 10 | 20 | 40,000 |
Plasma storage capacity in manufacturers.
| Babolsar | Babol | Sari | Behshahr |
|---|---|---|---|
| (2000,2500,3000) | (3000,4000,5000) | (3000,3500,4000) | (2000,2400,2800) |
The number of beds in the collection centers, the number of donors, and the capacity of the collection centers for working hours.
| No. | Collection centers | Empty beds | Number of normal donors | Total capacity of normal blood donors during working hours |
|---|---|---|---|---|
| 1 | Center 1 | 100 | 151 | 50 |
| 2 | Center 2 | 300 | 216 | 40 |
| 3 | Center 3 | 300 | 408 | 70 |
| 4 | Center 4 | 200 | 311 | 30 |
| 5 | Center 5 | 150 | 325 | 20 |
| 6 | Center 6 | 100 | 200 | 20 |
| 7 | Center 7 | 200 | 155 | 30 |
| 8 | Center 8 | 100 | 108 | 30 |
| 9 | Center 9 | 200 | 318 | 50 |
| 10 | Center 10 | 300 | 523 | 60 |
Plasma demand in hospitals.
| No. | Hospital | Plasma Demand | |
|---|---|---|---|
| Period 1 | Period 2 | ||
| 1 | Mehr Behshahr | (280,300,320) | (300,350,400) |
| 2 | Amiri Behshahr | (400,450,500) | (400,450,500) |
| 3 | Bo Ali Neka | (220,250,280) | (250,300,350) |
| 4 | Bo Ali Sari | (500,540,580) | (450,460,470) |
| 5 | Zare Sari | (200,230,260) | (230,240,250) |
| 6 | Shafa Sari | (270,300,330) | (250,300,350) |
| 7 | Nime Shaban Sari | (450,500,550) | (410,450,490) |
| 8 | Amir Mzandarani Sari | (450,500,550) | (300,400,500) |
| 9 | Velayat Sari | (300,400,500) | (250,300,350) |
| 10 | Haj Azizi Juybar | (100,150,200) | (160,180,200) |
| 11 | Kudakan Babol | (400,500,600) | (340,370,400) |
| 12 | 17 Sahrivar Babol | (240,300,360) | (300,330,360) |
| 13 | Mehregan Babol | (150,250,350) | (150,250,350) |
| 14 | Hazrat Zeinab Babolsar | (200,300,400) | (170,210,250) |
| 15 | Shafa Babolsar | (400,450,500) | (380,400,420) |
The results of the case study.
| Period | Iteration number | Government Model | NGOs Model | |||
|---|---|---|---|---|---|---|
| Time (s) | Time (s) | |||||
| 576764 | 11 | 26 | 589403 | 8 | ||
| 167925 | 24 | 40 | 286997 | 16 | ||
| 302464 | 18 | 36 | 389502 | 8 | ||
| 254480 | 11 | 49 | 298581 | 15 | ||
| 198237 | 29 | 57 | 204511 | 20 | ||
The amount of perished plasma and allocated BCE technology.
| No. | Hospital | BCE assigned to hospital | Number of expired platelets | ||
|---|---|---|---|---|---|
| Period 1 | Period 2 | Period 1 | Period 2 | ||
| 1 | Mehr Behshahr | 1 | 0 | 8 | 5 |
| 2 | Amiri Behshahr | 0 | 1 | 11 | 0 |
| 3 | Bo Ali Neka | 1 | 0 | 5 | 0 |
| 4 | Bo Ali Sari | 1 | 1 | 9 | 13 |
| 5 | Zare Sari | 1 | 1 | 0 | 0 |
| 6 | Shafa Sari | 0 | 0 | 10 | 10 |
| 7 | Nime Shaban Sari | 0 | 1 | 0 | 0 |
| 8 | Amir Mzandarani Sari | 1 | 1 | 0 | 0 |
| 9 | Velayat Sari | 1 | 0 | 5 | 10 |
| 10 | Haj Azizi Juybar | 0 | 0 | 0 | 0 |
| 11 | Kudakan Babol | 1 | 1 | 0 | 0 |
| 12 | 17 Sahrivar Babol | 0 | 0 | 0 | 19 |
| 13 | Mehregan Babol | 0 | 0 | 9 | 10 |
| 14 | Hazrat Zeinab Babolsar | 1 | 1 | 15 | 15 |
| 15 | Shafa Babolsar | 1 | 1 | 8 | 0 |
The number of donors attracted by advertisements.
| No. | Collection center | Period 1 | Period 2 | ||||
|---|---|---|---|---|---|---|---|
| Social networks | TV ads | banners | Social networks | TV ads | banners | ||
| 1 | Center 1 | 55 | 41 | 44 | 68 | 89 | 60 |
| 2 | Center 2 | 148 | 64 | 26 | 154 | 57 | 44 |
| 3 | Center 3 | 229 | 86 | 70 | 287 | 49 | 25 |
| 4 | Center 4 | 185 | 93 | 62 | 337 | 85 | 76 |
| 5 | Center 5 | 271 | 108 | 29 | 187 | 98 | 73 |
| 6 | Center 6 | 78 | 52 | 38 | 102 | 96 | 62 |
| 7 | Center 7 | 109 | 63 | 39 | 73 | 87 | 31 |
| 8 | Center 8 | 68 | 10 | 10 | 73 | 54 | 41 |
| 9 | Center 9 | 86 | 62 | 59 | 279 | 145 | 103 |
| 10 | Center 10 | 266 | 128 | 100 | 311 | 258 | 127 |
| Sum | 1495 | 707 | 477 | 1871 | 1018 | 642 | |
The amount of platelet shortage.
| No. | Hospital | The amount of platelet shortage | |
|---|---|---|---|
| Period 1 | Period 2 | ||
| 1 | Mehr Behshahr | 12 | 2 |
| 2 | Amiri Behshahr | 0 | 0 |
| 3 | Bo Ali Neka | 5 | 11 |
| 4 | Bo Ali Sari | 13 | 19 |
| 5 | Zare Sari | 16 | 10 |
| 6 | Shafa Sari | 5 | 0 |
| 7 | Nime Shaban Sari | 11 | 0 |
| 8 | Amir Mzandarani Sari | 10 | 28 |
| 9 | Velayat Sari | 14 | 22 |
| 10 | Haj Azizi Juybar | 9 | 0 |
| 11 | Kudakan Babol | 0 | 0 |
| 12 | 17 Sahrivar Babol | 25 | 16 |
| 13 | Mehregan Babol | 8 | 8 |
| 14 | Hazrat Zeinab Babolsar | 5 | 0 |
| 15 | Shafa Babolsar | 18 | 11 |
Fig. 3The sensitivity analysis of the player costs based on demand variations.
Fig. 4The sensitivity analysis of costs based on donor's willingness to donate blood to the collection center.
Fig. 5The sensitivity analysis of the player costs coefficient based on desirability of NGOs
Donor and donation agents to consider keeping a sufficient supply of blood in the COVID-19 pandemic condition.
| Considerations | Possible actions | |
|---|---|---|
| Availability of personnel | Influence of COVID-19 on personnel: fear of disease, sickness, quarantine | Encouraging employees to self-report sickness or concerns; Contingency plans to replace staff have to prepare (For example change jobs and train other unnecessary personnel). Providing the psychological support of personnel Employing clear support policies for sick leave. |
| Inventory management | Demand is difficult to forespeak and may vary at various stages of the epidemic | Stay in touch with hospital customers, containing control activities that need to raise blood utilization (for instance transplantation and elective surgery) evaluate the entire system inventory closely; regular inventory updates. |
| Protection of donors and personnel | Utilization of private protective equipment for volunteers, personnel, donors; controlling COVID-19 patients between donors and personnel; practicing the distance of the physical; the messages of the donors before entering the blood center about virtue, health, safety, and goodness; Pretesting for signs and symptoms of COVID-19 patients | Checking the availability of private protective equipment; Enforcing a communication program for job risk; Coordinating actions with public health recommendations; Screening for temperatures and symptoms before entering centers and sites for donors, volunteers, and personnel; Disseminating guidelines for COVID-19 symptoms and signs between donors, volunteers, and personnel (testing, quarantine, etc.); |
Approaches to priorities blood utilization for COVID-19 sick in hospitals according to the forespoken shortage.
| Considerations | Possible actions | |
|---|---|---|
| Major bleeding | The shortages of the blood for sick with bleeding | Reviewing local policies that are according to the utilization of blood components by ratio-driven therapy is defined, 1:1 for plasma and red blood cells if platelets are not existing or preferably 1:1:1 for platelets, plasma, and red blood cells; If frozen plasma or cryoprecipitate is in short supply for sick with bleeding, consider prothrombin complex concentrate and fibrinogen concentrates; Considering the plasma first or blood components at ratios of 1:2:1 (platelets, plasma, and red blood cells), If red blood cells are in short supply; Providing the utilization of the plasma of type A to transport massively, if the plasma of the type AB is unavailable; Considering cold-stored or frozen platelets, or whole blood, if platelets are scarce. |
| The usage of the red blood cells | The shortages of the red blood cells | Examining the red blood cell transfusions threshold for sick who are low risk and stable (for example children and adults along with moderate symptoms) |
| Alternatives for blood injection | Confirming the utilization of alternatives to blood injection during periods of shortages of the blood | Tranexamic acid has to provide for sick with outpatients with chronic thrombocytopenia or severe hypo proliferative thrombocytopenia; Desmopressin has to consider for sick with inherited platelet disorders or uremia who are at bleeding risk since there are little data for other sick populations; Guarantee that alternative actions for raising hemoglobin are provided if it is needed (For example erythropoietin and parenteral iron). |
| The use of platelet | The shortages of the Platelet to transport the prophylactic | The platelets usage as prophylaxis have to restrict in sick with hypo proliferative thrombocytopenia without clinical bleeding containing autologous transplantation |
| Set of donors indexed by | |
| Set of collection center indexed by | |
| Set of manufacturers indexed by | |
| Set of hospital indexed by | |
| Set of advertisement indexed by | |
| Set of gender indexed by | |
| Set of the age of plasma indexed by | |
| Set of time periods indexed by | |
| Set of method indexed by | |
| α | 1, if donor |
| β | 1, if donor |
| δ | 1, if donor |
| ρ | 1, if donor |
| ϑ | 1, if donor |
| γ | 1, if donor |
| γ′ | 1, if donor |
| μ | Level of the effectiveness of collection center |
| Φ | Donor |
| The cost of collection one blood unit that taken from a second type donor in hospital | |
| The cost of producing one plasma unit by the manufacturer | |
| The cost of collection one blood unit by collection center | |
| The cost of purchasing and transporting a unit of blood from an unreserved donor from the collection center | |
| The cost of purchasing and transporting a unit of blood from an unreserved donor from the collection center | |
| Start-up cost in manufacturer | |
| Cost of corruption in hospital | |
| Cost of corruption in manufacturer | |
| Cost of shortage in hospital | |
| Cost of advertising type | |
| The holding cost a plasma unit in the manufacturer | |
| The holding cost a plasma unit in hospital | |
| The cost of transporting a unit of blood from hospital | |
| The cost of transporting a unit of plasma from manufacturer | |
| Cost of BCE allocation in hospital | |
| The cost of overtime at the collection center | |
| The cost of using method | |
| Maximum number of available BCE | |
| Plasma storage capacity in hospital | |
| Plasma storage capacity in manufacturer | |
| Total capacity of donors at the collection center | |
| Total capacity of donors at the collection center | |
| Capacity of produce plasma at manufacturer | |
| Attraction rate of donors for advertising type | |
| Amount of plasma confidence inventory with stored age | |
| The amount of blood unit taken from a donor with gender | |
| The number of reserved and unreserved recovered donors at collection center | |
| Plasma demand in hospital | |
| The number of second type donors that enrolled in hospital | |
| A big number | |
| The number of empty beds in the collection center | |
| 1, If hospital | |
| 1, If plasma are produced in the manufacturer | |
| 1, If unreserved donor | |
| 1, If BCE is assigned to hospital | |
| Inventory of plasma with age | |
| Inventory of plasma with age | |
| Fraction of maximum demand for plasma with age | |
| The amount of plasma shortage with age | |
| The number of registered unreserved donors with gender | |
| The number of registered unreserved donors with gender | |
| The number of unreserved donors with gender | |
| The total amount of prepared blood from donors with gender | |
| The number of donors attracted by type | |
| The number of donors attracted by type | |
| The number of transferred bloods from hospital | |
| The number of produced bloods by a second type donor with gender | |
| The number of expired plasma in the manufacturer | |
| The number of expired plasma in hospital | |
| The amount of produced plasma from gender | |